Drug makers’ downsizing moves continue unabated in Japan. In the past three months alone, it was revealed that voluntary redundancy programs were being planned or launched for Pfizer, MSD, and Sanofi, affecting a total of over 600 staffers mainly in…
HOME > COLUMN
COLUMN
- When Leading Teams, Focus on the Principles, Not the Personalities
January 26, 2018
- What to Do about the Feeling of Torschlusspanik?
October 27, 2017
- Women! Rock the Boat and Get Promoted
September 22, 2017
- Getting the Right Message
August 25, 2017
- Putting on Your Pants
July 21, 2017
- Reputable Combination
July 11, 2017
- What Is the Best Path to Customers’ Hearts and Minds?
June 19, 2017
- Doubling Down on Digital
May 26, 2017
- Global Opportunities for Global Minds
April 21, 2017
- Will Tepid Pricing Debate Only Go Full-Throttle after Golden Week Holidays?
March 30, 2017
- Some Japanese Pharmaceutical Workers May Slowly Be Working Themselves to Death
March 17, 2017
- The Best Recruiters Are Just a Little Paranoid
February 17, 2017
- 5 Killer Questions for HR to Ask Recruiters
January 20, 2017
- What Pharma Can Learn from the Airline Industry
December 16, 2016
- Near Death at Singapore General Hospital and 5 Lessons I Learnt
October 20, 2016
- Reasons for a “Hold”
August 9, 2016
- It’s Time for Market Access to Play a Leading Role
April 22, 2016
- Biosimilars Are the New Black
March 25, 2016
- Technology Provides Opportunities for Medical Device Companies
February 18, 2016
- Don’t Accept the Offer
January 22, 2016
ページ
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In my home country of Australia, there is a famous candy called “Minties”. Minties has a long-running advertising campaign, presenting comical situations, with the caption, “It’s moments like these.” The phase has become part of the Aussie vernacular, meaning in…